Pulmonary hypertension in patients with chronic myeloproliferative disorders

European Respiratory Journal

Volumn 35, Issue 6, 2010, Pages 1396-1406

  Adir, Y ^a   Humbert, M ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Universite Paris Sud   (France)

Author keywords

Chronic thromboembolic pulmonary hypertension; Essential thrombocytosis; Myeloproliferative disorders; Polycythaemia vera; Pulmonary hypertension; Pulmonary veno occlusive disease

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DASATINIB; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYUREA; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN DERIVATIVE; VASODILATOR AGENT;

BLEEDING; CHRONIC MYELOID LEUKEMIA; DISEASE CLASSIFICATION; HUMAN; LOW DRUG DOSE; MYELOPROLIFERATIVE DISORDER; OXYGEN THERAPY; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; REVIEW; THROMBOSIS; VASCULAR DISEASE; WORLD HEALTH ORGANIZATION;

CHRONIC DISEASE; HUMANS; HYPERTENSION, PULMONARY; INCIDENCE; MYELOPROLIFERATIVE DISORDERS; PREVALENCE;

EID: 77953519933     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00175909     Document Type: Review

References (106)

1. Rubin L. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-117.
2. Simonneau G, Robbins IM, Beghetti M, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 30: Suppl. 1, S43-S54.
3. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-1619.
4. Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th Edn. Geneva, World Health Organization, 2008.
5. Groffen J, Stephenson JR, Heisterkamp N, et al. Philadelphia chromosomal breakpoints are clustered within a limited region bcr on chromosome 22. Cell 1984; 36: 93-96. (Pubitemid 14155374)
6. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK-2 in myeloproliferative disorders. N Engl J Med 2005; 352: 1779-1790.
7. Hellmann A. Myeloproliferative syndromes: diagnosis and therapeutic options. Pol Arch Med 2008; 118: 756-760.
8. Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190-2198.
9. Reisner SA, Rinkevich D, Markiewicz W, et al. Cardiac involvement in patients with myeloproliferative disorders. Am J Med 1992; 93: 498-504.
10. Garypidou V, Vakalopoulou S, Dimitriadis D, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. Haematologica 2004; 89: 245-247.
11. Altintas A, Karahan Z, Pasa S, et al. Pulmonary hypertension in patients with essential thrombocythemia and reactive thrombocytosis. Leuk Lymphoma 2007; 48: 1981-1987.
12. Gupta R, Perumandla S, Patsiornik Y, et al. Incidence of pulmonary hypertension in patients with chronic myeloproliferative disorders. J Natl Med Assoc 2006; 98: 1779-1782. (Pubitemid 44885533)
13. Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008; 22: 646-649.
14. Guilpain P, Montani D, Damaj G, et al. Pulmonary hypertension associated with myeloproliferative disorders: a retrospective study of ten cases. Respiration 2008; 76: 295-302.
15. Dingli D, Utz JP, Krowka MJ, et al. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001; 120: 801-808.
16. Garcia-Manero G, Schuster SJ, Patrick H, et al. Pulmonary hypertension in patients with myelofibrosis secondary to myeloproliferative diseases. Am J Hematol 1999; 60: 130-135.
17. Marvin KS, Spellberg RD. Pulmonary hypertension secondary to thrombocytosis in a patient with myeloid metaplasia. Chest 1993; 103: 642-644.
18. Hill G, McClean D, Fraser R, et al. Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. Aust NZ J Med 1996; 26: 852-853. (Pubitemid 127495281)
19. Nand S, Orfei E. Pulmonary hypertension in polycythemia vera. Am J Hematol 1994; 47: 242-244.
20. Popat U, Frost A, Liu E, et al. New onset of myelofibrosis in association with pulmonary arterial hypertension. Ann Intern Med 2005; 143: 466-467. (Pubitemid 41338947)
21. Ziakas PD, Voulgarelis M, Felekouras E, et al. Myelofibrosis-associated massive splenomegaly. A cause of increased intra-abdominal pressure, pulmonary hypertension, and positional dyspnea. Am J Hematol 2005; 80: 128-132.
22. Di Stefano F. Pulmonary arterial hypertension and chronic myeloproliferative disorders. Am J Respir Crit Care Med 2006; 174: 616.
23. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263.
24. Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493-2537.
25. Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22: 2020-2028.
26. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005; 23: 2224-2232.
27. Wehmeier A, Daum I, Jamin H, et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63: 101-106.
28. Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-664.
29. Chim CS, Kwong YL, Lie AK, et al. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005; 165: 2651-2658.
30. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia 1999; 13: 150-154.
31. Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc 2006; 81: 159-166.
32. Jensen MK, de Nelly Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in well defined geographical area. Eur J Hematol 2000; 65: 132-139.
33. Colombi M, Radaelli F, Zocchi L, et al. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926-3290.
34. Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556.
35. Kwaan HC, Wang J. Hyperviscosity in polycythemia vera and other red cell abnormalities. Semin Thromb Hemost 2003; 29: 451-458.
36. Turitto VT, Weiss HJ. Platelet and red cell involvement in mural thrombogenesis. Ann NY Acad Sci 1983; 416: 363-376. (Pubitemid 14140663)
37. Huang PY, Hellums JD. Aggregation and disaggregation kinetics of human blood platelets: the disaggregation under shear stress of platelet aggregates. Biophys J 1993; 65: 354-361. (Pubitemid 23206068)
38. Valla D, Casadevall N, Lacombe C, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985; 103: 329-334.
39. De Stefano V, Teofili L, Leone G, et al. Spontaneous erythroid colony formation as the clue to an underlying myeloproliferative disorder in patients with Budd-Chiari syndrome or portal vein thrombosis. Semin Thromb Haemost 1997; 23: 411-418. (Pubitemid 27501780)
40. Vannucchi AM, Grossi A, Pancrazzi A, et al. PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. Br J Haematol 2004; 127: 214-219.
41. Michiels JJ, Berneman Z, Bockstaele DV, et al. Clinical and laboratory features, pathology of platelet-mediated thrombosis and bleeding complications and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications. Semin Thromb Hemost 2006; 32: 174-207.
42. Buss DH, Stuart JJ, Lipscomb GE. The incidence of thrombotic and hemorrhagic disorders in association with extreme thrombocytosis: an analysis of 129 cases. Am J Hematol 1985; 20: 365-372.
43. Wehmeier A, Südhoff T, Meierkord F. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders. Semin Thromb Hemost 1997; 23: 391-402. (Pubitemid 27360081)
44. Landolfi R, Ciabattoni G, Patrignani P, et al. Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood 1992; 80: 1965-1971.
45. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia 2007; 21: 1218-1223.
46. Carobbio A, Finazzi G, Guerini V, et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors and Jak2 mutation status. Blood 2007; 109: 2310-2313. (Pubitemid 46425868)
47. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005; 365: 1054-1061.
48. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005; 434: 1144-1148. (Pubitemid 40663494)
49. Cazzola M, Skoda R. Gain of function, loss of control F a molecular basis for chronic myeloproliferative disorders. Haematologica 2005; 90: 871-874. (Pubitemid 41020289)
50. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005; 366: 1945-1953.
51. Arellano-Rodrigo E, Alvarez-Larran A, Reverter JC, et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 2006; 91: 169-175. (Pubitemid 43304135)
52. Falanga A, Marchetti M, Vignoli A, et al. V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules. Exp Hematol 2007; 35: 702-711. (Pubitemid 46601748)
53. Kiladjian JJ, Cervantes F, Leebeek FW, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008; 111: 4922-4929.
54. Pardanani A, Lasho TL, Hussein K, et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457-459.
55. Hirsch J, Dacie V. Persistent post-splenectomy thrombocytosis and thrombo-embolism: a consequence of continuing anemia. Br J Haematol 1966; 12: 44-53.
56. Mohren M, Markmann I, Dworschak U, et al. Thromboembolic complications after splenectomy for hematologic diseases. Am J Hematol 2004; 76: 143-146.
57. Chaffanjon CJ, Brichon P, Ranchoup Y, et al. Portal vein thrombosis following splenectomy for hematologic disease: prospective study with Doppler color flow imaging. World J Surg 1998; 22: 1082-1086.
58. Van't riet M, Burger J, Van Muiswinkel JM, et al. Diagnosis and treatment of portal vein thrombosis following splenectomy. Br J Surg 2000; 87: 1229-1233.
59. Tefferi A, Mesa R, Nagorney DM, et al. Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. Blood 2000; 95: 2226-2233. (Pubitemid 30167718)
60. Bonderman D, Wilkens H, Wakounig S, et al. Risk factors for chronic thromboembolic pulmonary hypertension. Eur Respir J 2009; 33: 325-331.
61. Jais X, Ioos V, Jardim C, et al. Splenectomy and chronic thromboembolic pulmonary hypertension. Thorax 2005; 60: 1031-1034.
62. Boxer MA, Braun J, Ellman L. Thromboembolic risk of postsplenectomy thrombocytosis. Arch Surg 1978; 113: 808-809.
63. Visudhiphan S, Ketsa-Ard K, Piankijagun A, et al. Blood coagulation and platelet profiles in persistent post splenectomy thrombocytosis. The relationship to thromboembolism. Biomed Pharmacother 1985; 39: 264-271.
64. Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipids asymmetry in human thalassemia. Blood 1998; 91: 3044-3051. (Pubitemid 28227558)
65. Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E/b-thalassemic patients. Br J Haematol 2002; 118: 893-898.
66. Hirsh J, Guyatt G, Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: Suppl. 6, 110-112.
67. Cappellini MP, Grespi E, Cassinerio E, et al. Coagulation and splenectomy: an overview. Ann NY Acad Sci 2005; 1054: 317-324.
68. Fedullo PF, Auger WR, Kerr KM, et al. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001; 345: 1465-1472.
69. Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28: 138-143. (Pubitemid 44914271)
70. Seyfarth HJ, Hammerschmidt S, Pankau H, et al. Long-term bosentan in chronic thromboembolic pulmonary hypertension. Respiration 2007; 74: 287-292.
71. Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123: 338-343. (Pubitemid 36269413)
72. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329. (Pubitemid 34815354)
73. Wilkins MR, Wharton J, Grimminger F, et al. Phosphodiesterase inhibitors for the treatment of pulmonary hypertension. Eur Respir J 2008; 32: 198-209.
74. Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2008; 31: 759-764.
75. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995; 332: 1132-1136.
76. Fruchtman SM, Mack K, Kaplan ME, et al. From efficacy to safety: a polycythemia vera study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997; 34: 17-23. (Pubitemid 27063138)
77. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005; 353: 33-45.
78. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4: 2593-2598.
79. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low dose aspirin in polycythemia vera.N Engl J Med 2004; 350: 114-124.
80. Van Genderen PJ, Mulder PG, Waleboer M, et al. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 1997; 97: 179-184. (Pubitemid 27179585)
81. Ito H, Adachi Y, Arimura Y, et al. A 25-year clinical history of portopulmonary hypertension associated with latent myeloproliferative disorder. J Gastroenterol 2003; 38: 488-492.
82. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000; 342: 1255-1265.
83. Ward HP, Block MH. The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. Medicine (Baltimore) 1971; 50: 357-420.
84. Montani D, Price LC, Dorfmuller P, et al. Pulmonary veno-occlusive disease. Eur Respir J 2009; 33: 189-200.
85. Willems E, Canivet JL, Ghaye B, et al. Pulmonary veno-occlusive disease inmyeloproliferative disorder. Eur Respir J 2009; 33: 213-216.
86. Adir Y, Yigla M, Amir O, et al. Pulmonary hypertension associated with myeloproliferative disorders suggesting pulmonary veno-occlusive disease: a retrospective study of six cases. Eur Respir J 2009; 34: Suppl. 53, 319s.
87. Halank M, Marx C, Baretton G, et al. Severe pulmonary hypertension in chronic idiopathic myelofibrosis. Onkologie 2004; 27: 472-474.
88. Hill G, McClean D, Fraser R, et al. Pulmonary hypertension as a consequence of alveolar capillary plugging by malignant megakaryocytes in essential thrombocythaemia. Aust NZ J Med 1996; 26: 852-853. (Pubitemid 127495281)
89. Dot JM, Sztrymf B, Yaïci A, et al. Pulmonary arterial hypertension due to tumor emboli. Rev Mal Respir 2007; 24: 359-366. (Pubitemid 46586964)
90. Hibbin JA, Njoku OS, Matutes E, et al. Myeloid progenitor cells in the circulation of patients with myelofibrosis and other myeloproliferative disorders. Br J Haematol 1984; 57: 495-503. (Pubitemid 14082100)
91. Haznedaroglu IC, Atalar E, Ozturk MA, et al. Thrombopoietin inside the pulmonary vessels in patients with and without pulmonary hypertension. Platelets 2002; 13: 395-399.
92. Koch CA, Li CY, Mesa RA, et al. Nonhepatosplenic extramedullary hematopoiesis: associated diseases, pathology, clinical course, and treatment. Mayo Clin Proc 2003; 78: 1223-1233.
93. Steensma DP, Hook CC, Stafford SL, et al. Low-dose, single fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002; 118: 813-816.
94. Weinschenker P, Kutner JM, Salvajoli JV, et al. Whole-pulmonary low-dose radiation therapy in agnogenic myeloid metaplasia with diffuse lung involvement. Am J Hematol 2002; 69: 277-280.
95. Neville RF, Sidawy AN. Myointimal hyperplasia: basic science and clinical considerations. Semin Vasc Surg 1998; 11: 142-148. (Pubitemid 28433877)
96. Perros F, Montani D, Dorfmüller P, et al. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008; 178: 81-88.
97. White SM, Wagner JG, Roth RA. Effects of altered platelet number on pulmonary hypertension and platelet sequestration in monocrotaline pyrrole-treated rats. Toxicol Appl Pharmacol 1989; 99: 302-313.
98. Zetterberg E, Popat U, Hasselbalch H, et al. Angiogenesis in pulmonary hypertension with myelofibrosis. Haematologica 2008; 93: 945-946.
99. Cortelezzi A, Gritti G, Del Papa N, et al. Pulmonary arterial hypertension in primary myelofibrosis is common and associated with an altered angiogenic status. Leukemia 2008; 22: 646-649.
100. Popat U, Frost A, Liu E, et al. High levels of circulating CD34 cells, dacrocytes, clonal hematopoiesis, and JAK2 mutation differentiate myelofibrosis with myeloid metaplasia from secondary myelofibrosis associated with pulmonary hypertension. Blood 2006; 107: 3486-3488.
101. Fadini GP, Schiavon M, Cantini M, et al. Circulating D34+ cells, pulmonary hypertension, and myelofibrosis. Blood 2006; 108: 1776-1777.
102. Quintas-Cardama A, Kantarjian H, O'Brien S, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908-3914.
103. Rasheed W, Flaim B, Seymour J. Reversible severe pulmonary hypertension secondary to dasatinib in a patient with chronic myeloid leukaemia. Leuk Res 2009; 33: 861-864.
104. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500-4505.
105. Souza R, Sitbon O, Parent F, et al. Long term imatinib treatment in pulmonary arterial hypertension. Thorax 2006; 61: 736.
106. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonaryarterial hypertension. N Engl J Med 2005; 353: 1412-1413.